Jupiter Neurosciences, Inc. (JUNS) to Raise $15 Million in IPO
Jupiter Neurosciences, Inc. (JUNS) to Raise $15 Million in IPO
$Jupiter Neurosciences (JUNS.US)$ is planning to raise $15 million in an initial public offering on the week of September 12th, IPO Scoop reports. The company will issue 2,500,000 shares at a price of $5.00-$7.00 per share.
$Jupiter Neurosciences (JUNS.US)$首次公開招股獨家報導，計劃在 9 月 12 日一周的首次公開發行中籌集 15 萬美元。該公司將以每股 5 至 7 美元的價格發行 25 萬股股票。
Spartan Capital served as the underwriter for the IPO.
斯巴達資本擔任首次公開募股的承銷商。
Jupiter Neurosciences, Inc. provided the following description of their company for its IPO: "(Note: On Aug. 16, 2022, Jupiter Neurosciences changed underwriters – to Spartan Capital as the sole book-runner – and revamped its IPO to a stock-only deal, dropping the warrants. The new terms: 2.5 million shares at $5.00 to $7.00 to raise $15.0 million, with the proposed stock symbol "JUNS" on the NASDAQ. On Aug. 26, 2022, Jupiter Neurosciences updated its S-1/A filing. **A 1-for-2 reverse stock split was effective Jan. 25, 2022; all share and per-share information in the prospectus have been adjusted to account for that event. For more details on this deal's filings, please see "Background" note at the end of this company's IPO Profile.) Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company that has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. The product candidate, called JOTROL, has many potential indications of use for rare diseases, which we primarily are targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and MELAS and with ALS in an earlier development stage. In the larger disease areas, we are primarily targeting Mild Cognitive Impairment/early Alzheimer's disease with an early development program in TBI (traumatic brain injury)/concussions. In 2020, we received approval for full funding, $1.76 million, for our Phase I study from the National Institute on Aging ("NIA"). We plan to continue pursuing grant funding opportunities in all areas where they are available, such as Phase II and Phase III trials in Alzheimer's disease as well as any funding available for our rare disease projects. In the NIA scientific review summary statement of our Phase I study application, it is stated that NIA is looking forward to a Phase II study with an enhanced resveratrol product, based on the earlier study results from the well published Turner et al. Alzheimer's study. We recently submitted a grant application to NIA for full funding, including corporate overhead for a total of $18.3 million, for the duration of the study, of a Phase II trial in Mild Cognitive Impairment (MCI) and early Alzheimer's disease. There is however no guarantee that this and future grant applications will be successful and therefore the rejection of our future grant application may significantly delay the Company's plans in connection with MCI and Alzheimer's and may have a significant impact on the Company's financial performance. Further, the Company may never receive any future grants or costs savings. (Background: This IPO's previous joint book-runners were Roth Capital and Dawson James Securities. Jupiter Neurosciences, Inc., revived its IPO – postponed on Thursday (Feb. 10, 2022) due to market conditions – in an S-1/A filing dated April 26, 2022; the unit deal was tentatively scheduled for pricing after the close on Feb. 10. Previously: Jupiter Neurosciences cut the size of its unit IPO to 2.2 million units, down from 3.33 million units, and increased the price range to $6 to $8, up from $5 to $7, in an S-1/A filing dated Jan. 26, 2022. Each unit consisted of one share of common stock and one warrant to buy one share of common stock. The proposed symbols are: "JUNS" for the stock and "JUNSW" for the warrants – NASDAQ listing.) ".
木星神經科學公司（Jupiter Neurosciences）在 IPO 上提供了以下對其公司的描述：「（注意：2022 年 8 月 16 日，木星神經科學公司改變了承銷商-作為唯一的賬簿管理人），並將其首次公開募股更改為僅股票交易，放棄了認股權證。新條款：250 萬股股票價格為 5.00 美元至 7.00 美元，籌集 15.0 萬美元，擬議的股票代碼為「JUNS」在納斯達克。2022 年 8 月 26 日，木星神經科學更新了其 S-1/A 文件。**1 對 2 的反向股票分割於 2022 年 1 月 25 日生效；招股說明書中的所有股份和每股信息均已根據該事件進行調整。有關此交易文件的更多詳細信息，請參閱該公司 IPO 簡介末尾的「背景」註釋。）Jupiter Neurosciences, Inc. 是一家臨床階段研究和開發製藥公司，已開發出一種獨特的白藜蘆醇平台產品，主要針對神經炎症的治療。該產品候選產品稱為 JOTROL，具有許多用於罕見疾病的潛在適應症，我們主要針對粘多糖病 1 型，弗里德瑞希共濟失調，MELAS 以及 ALS 在較早的開發階段。在較大的疾病領域，我們主要針對輕度認知障礙/早期阿爾茨海默氏病，並在 TBI（創傷性腦損傷）/腦震盪中進行早期發展計劃。2020 年，我們獲得了美國國家老齡化研究所（「NIA」）的第一階段研究的批准，以獲得 1.76 萬美元的全額資金。我們計劃繼續在所有可用領域尋求補助金的機會，例如阿爾茨海默氏病的 II 期和 III 期試驗，以及為我們罕見疾病項目提供的任何資金。在 NIA 第一期研究申請書的科學評論摘要聲明中，根據公佈的 Turner et al 早期研究結果，NIA 期待進行具有增強型白藜蘆醇產品的 II 期研究。阿茲海默氏症研究。我們最近向 NIA 提交了撥款申請，以全額資助，包括在研究期間，總計為 18.3 百萬美元的公司開銷輕度認知障礙（MCI）和早期阿爾茨海默氏病的 II 期試驗。然而，我們並不能保證此項和未來的撥款申請將會成功，因此拒絕我們未來的贈款申請可能會大大延遲公司與 MCI 和阿爾茨海默氏症有關的計劃，並可能對公司的財務績效產生重大影響。此外，公司可能永遠不會收到任何未來的贈款或節省成本。（背景：本次公開招股之前的聯席賬簿管理人是羅斯資本和道森詹姆斯證券。木星神經科學有限公司在 2022 年 4 月 26 日的 S-1/A 文件中恢復了 IPO-由於市場條件，於 2022 年 2 月 10 日（星期四）推遲-該單位交易暫定於 2 月 10 日收盤後進行定價。以前：木星神經科學在 2022 年 1 月 26 日的 S-1/A 文件中，木星神經科學將其單位 IPO 的規模從 330 萬台減少到 220 萬台，並將價格範圍從 5 美元增加到 8 美元，從 5 美元增加到 7 美元。每個單位包括一股普通股及一份購買一股普通股的權證。建議的代號為：股票的「JUNS」和「JUNSW」（認股證 — 納斯達克上市）。
Jupiter Neurosciences, Inc. was founded in 2016 and has 5 employees. The company is located at Jupiter Neurosciences, Inc. 1001 North US HWY 1, Suite 504 Jupiter, Florida 33477 and can be reached via phone at (561) 406-6154 or on the web at
木星神經科學有限公司成立於 2016 年，擁有 5 名員工。該公司位於木星神經科學有限公司 1001 美國北部高速公路 1 號，504 號木星套房，佛羅里達州 33477，可以通過電話（561）406-6154 或在網絡上與以下網址聯繫：
Receive News & Ratings for Jupiter Neurosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jupiter Neurosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收木星神經科學公司的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關木星神經科學公司及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。